Major Challenges in Providing an Effective and Timely Pandemic Vaccine for Influenza A(H7N9)
Authors:
- Michael T. OsterholmMOMichael T. Osterholm
- Katie S. BalleringKBKatie S. Ballering
- Nicholas S. KelleyNKNicholas S. Kelley
- 26 June 2013
- journal article
- viewpoint
- Published by American Medical Association (AMA) in JAMA
- Vol. 309 (24) , 2557-2558
Abstract
The emergence of avian influenza A(H7N9) virus in humans has public health authorities around the world on high alert for the potential development of a human iKeywords
This publication has 4 references indexed in Scilit:
- Global production capacity of seasonal influenza vaccine in 2011Vaccine, 2013
- A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) VaccinePLOS ONE, 2012
- A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adultsVaccine, 2009
- A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccineVaccine, 2009